At a glance
ClinicalIndex Comparison RecordPhase 4Completed· 73 enrolled
Drug / intervention
Inhaled treprostinildrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
An Open Label, Multi-center Study Evaluating the Safety of Long-term Inhaled Treprostinil Administration Following Transition From Inhaled Ventavis® (Iloprost) in Subjects With Pulmonary Arterial Hypertension.
In Brief
A Phase 4 clinical trial evaluating Inhaled treprostinil for Pulmonary Arterial Hypertension. Completed, enrolled 73 participants across 15 sites.
Detailed Summary
This is a 24-month, multi-center, prospective, open-label, safety evaluation in PAH subjects following transition from a stable dose of inhaled iloprost (Ventavis). Subjects are to be evaluated for safety throughout the course of the study while secondary assessments will be conducted at Baseline, Week 6, Week 12, and Months 6, 12, 18 and 24 following initiation of treprostinil sodium.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPulmonary Arterial Hypertension
CountriesUnited States
Collaborators--
Timeline
Phase 4CompletedFinished
200920102011201220132014201520162017201820192020202120222023202420252026
First PostedAug 2008
Enrollment StartSep 2008
Primary CompletionMar 2010
Study CompletionDec 2010
TodayJul 2026
First PostedAug 26, 2008
Enrollment StartSep 1, 2008
Primary CompletionMar 1, 2010
Study CompletionDec 1, 2010
TodayJul 2, 2026
Enrollment to primary: 1.5 yearsPosted 17.8 years ago
Interventions
Inhaled treprostinildrug